Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SDS-20244
- Development stage
- Preclinical
- Lead developer
- Dayananda Sagar University
- Modality
- Small Molecules
01
Overview
SDS-20244 is a novel coumarin derivative synthesized from 7-hydroxy-4-methyl coumarin [1]. It acts as a monoamine oxidase B (MAO-B) inhibitor and exhibits neuroprotective and antioxidant properties [1]. In preclinical studies using a haloperidol-induced Parkinsonian rat model, SDS-20244 demonstrated significant neuroprotective efficacy, improving locomotor activity and motor coordination, increasing dopamine and superoxide dismutase (SOD) levels, and reducing lipid peroxidation (LPO) and acetylcholinesterase (AchE) activity [1].
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on SDS-20244.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SDS-20244.